51. Scleroderma
466 clinical trials,   536 drugs   (DrugBank: 142 drugs),   110 drug target genes,   210 drug target pathways

Searched query = "Scleroderma", "Systemic sclerosis", "SSc", "dcSSc", "lcSSc"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00043706
(ClinicalTrials.gov)
May 200212/8/2002Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic SclerosisA Phase 1/2 Double Blind, Placebo Controlled, Randomized, Dose Ranging, Repeat Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of CAT-192 Human Anti-TGF-Beta1 Monoclonal Antibody in Patients With Early Stage Diffuse Systemic SclerosisSystemic Sclerosis;SclerodermaDrug: Human Anti-Transforming Growth Factor Beta-1 Monoclonal AntibodyGenzyme, a Sanofi CompanyCambridge Antibody TechnologyCompleted18 Years75 YearsBothPhase 1;Phase 2United States